“Selling” Patents to Sovereign Nations Shouldn’t Mean Bad Patents Can’t Be Challenged



  • On September 8, 2017, the multi-billion dollar pharmaceutical company Allergan announced that it “sold” its patents relating to its eye drops drug “Restasis” to the Saint Regis Mohawk Tribe. But this was not a usual “sale.” The Tribe doesn’t appear to have paid anything in exchange for becoming the legal owner of Allergan’s patents. Instead, Allergan paid the Tribe $13.75 million, and also agreed to pay the Tribe up to $15 million more each year in exclusive licensing fees.

    Last week, EFF and Public Knowledge explained to the Patent Office how Allergan and the Tribe’s deal doesn’t mean Allergan’s bad patents can’t be challenged.

    The reason that Allergan and the Tribe engaged in this deal is not a secret. Both Allergan and the Tribe [PDF] readily admit the deal was done to try to prevent Allergan’s patents from being revoked through a Patent Office procedure known as “inter partes review.” Inter partes review allows any member of the public to challenge a patent as improperly granted based on the fact that what the patent claims as an invention was known to the public, or was an obvious change from information and innovation already held by the public.

    Allergan and the Tribe’s deal, through the assertion of “sovereign immunity,” tries to prevent the Patent Office from reviewing whether the patents were improperly granted. Generally, sovereign immunity refers to the concept that a sovereign entity (here the Tribe) can’t be subject to the jurisdiction of another sovereign (here the Patent Office) unless the entity agrees. The deal between Allergan and the Tribe requires the Tribe to assert sovereign immunity in an attempt to end the Patent Office procedures before the Restasis patents are revoked.

    Stated more bluntly, Allergan paid the tribe in order to block attempts to have its patents invalidated. A decision revoking the patents would lead to generic competition and lower consumer prices for Restasis. A determination that the patents can’t be challenged at the Patent Office could lead to the patents preventing generic entry and keeping prices artificially high.

    This deal has significant ramifications for the patent system if it is successful. As one judge described the deal:

    What Allergan seeks is the right to continue to enjoy the considerable benefits of the U.S. patent system without accepting the limits that Congress has placed on those benefits through the administrative mechanism for canceling invalid patents.

    Shortly after announcing the deal, the Tribe asked the Patent Office to end the proceedings, saying that since the Tribe owns the patents, the Patent Office has no authority to reconsider their legitimacy without the Tribe’s consent. The generic companies have opposed this motion on various grounds, arguing that the proceeding can continue. The Patent Office, perhaps in recognition of the significant controversy generated by the Allergan-Tribe deal, asked the public to weigh in as to whether the proceeding needed to be terminated.

    On November 30, 2017, EFF and Public Knowledge submitted a brief arguing that the Patent Office has all the authority it needs to continue the inter partes review proceeding, despite the Tribe’s sovereign immunity. We argued that the proceeding was not one that required the Tribe’s presence at all, meaning sovereign immunity had no application. We also suggested that the Patent Office consider asking its question in a more accessible proceeding, so that more voices could be heard.

    EFF and Public Knowledge were not the only parties to weigh in on this high profile dispute. Papers were also filed by other sovereign tribes, scholars, public interest groups, and industry representatives. All briefs are available through the Patent Office’s public portal, available here by searching for AIA Review Number IPR2016-01127.

    It may turn out that this dispute is irrelevant in the short term, as after the deal was announced, a federal court invalidated the patents (that decision is on appeal). Regardless of the outcome with respect to the Restasis patents, however, it is clear that other patent holders are engaging in similar deals [PDF] with sovereign tribes. EFF is pushing back against these deals as an improper assertion of sovereign immunity.

    https://www.eff.org/deeplinks/2017/12/selling-patents-sovereign-nations-shouldnt-mean-bad-patents-cant-be-challenged


 



Tmux Commands

screen and tmux

A comparison of the features (or more-so just a table of notes for accessing some of those features) for GNU screen and BSD-licensed tmux.

The formatting here is simple enough to understand (I would hope). ^ means ctrl+, so ^x is ctrl+x. M- means meta (generally left-alt or escape)+, so M-x is left-alt+x

It should be noted that this is no where near a full feature-set of either group. This - being a cheat-sheet - is just to point out the most very basic features to get you on the road.

Trust the developers and manpage writers more than me. This document is originally from 2009 when tmux was still new - since then both of these programs have had many updates and features added (not all of which have been dutifully noted here).

Action tmux screen
start a new session tmux OR
tmux new OR
tmux new-session
screen
re-attach a detached session tmux attach OR
tmux attach-session
screen-r
re-attach an attached session (detaching it from elsewhere) tmux attach -d OR
tmux attach-session -d
screen -dr
re-attach an attached session (keeping it attached elsewhere) tmux attach OR
tmux attach-session
screen -x
detach from currently attached session ^b d OR
^b :detach
^a ^d OR
^a :detach
rename-window to newname ^b , <newname> OR
^b :rename-window <newn>
^a A <newname>
list windows ^b w ^a w
list windows in chooseable menu ^a "
go to window # ^b # ^a #
go to last-active window ^b l ^a ^a
go to next window ^b n ^a n
go to previous window ^b p ^a p
see keybindings ^b ? ^a ?
list sessions ^b s OR
tmux ls OR
tmux list-sessions
screen -ls
toggle visual bell ^a ^g
create another window ^b c ^a c
exit current shell/window ^d ^d
split window/pane horizontally ^b " ^a S
split window/pane vertically ^b % ^a |
switch to other pane ^b o ^a <tab>
kill the current pane ^b x OR (logout/^D)
collapse the current pane/split (but leave processes running) ^a X
cycle location of panes ^b ^o
swap current pane with previous ^b {
swap current pane with next ^b }
show time ^b t
show numeric values of panes ^b q
toggle zoom-state of current pane (maximize/return current pane) ^b z
break the current pane out of its window (to form new window) ^b !
re-arrange current panels within same window (different layouts) ^b [space]
Kill the current window (and all panes within) ^b killw [target-window]
  • ?

    Клуб #RAZBOGATEI - ВЫПЛАЧИВАЕТ ИСПРАВНО

    https://razbogatei.com/p/esif22

    НЕ УПУСТИ ШАНС РАЗБОГАТЕТЬ НА 7 000 000 ? СТУДЕНТ ВХОД 100 РУБЛЕЙ ВЫХОД - 699 600 ? СТАЖЁР ВХОД 200 РУБЛЕЙ ВЫХОД - 1 399 200 ? МЕНЕДЖЕР ВХОД 300 РУБЛЕЙ ВЫХОД - 2 098 800 ? ДИРЕКТОР ВХОД 400 РУБЛЕЙ ВЫХОД - 2 798 400 ? НОВЫЙ ТАРИФ “БОСС” ВХОД 1500 РУБЛЕЙ ВЫХОД - 7 000 000 ?

    ПАССИВНЫЙ ЗАРАБОТОК - “приглашать” и пр. никого не надо!!!

    Не Обязательно Быть Умнее Других - Надо Стараться Быть Раньше Многих!!! Проекту ВСЕГО несколько дней! Мы - первые по подключениям!!! Успей вступить в первых рядах на самой верхушке!

    Регистрация, Активация https://razbogatei.com/p/esif22

    #млм #работанадому #бизнесонлайн #зароботоквсети #РЕФЕРАЛЫ

    read more
  • sort -g /var/log/nginx/access.log | awk '{print $1}' | uniq

    read more
});